

Omadacycline (PTK 0796) Publications/Posters

Publications				
Date	Journal	Citation	First Author	Title
Feb, 2017	Antimicrob. Agents and Chemother.	Accepted, epub ahead of print	Lepak	In vivo Pharmacodynamic Evaluation of Omadacycline (PTK 0796) against Streptococcus pneumoniae in the Murine Pneumonia Model
Dec, 2016	Antimicrob. Agents and Chemother.	Accepted, epub ahead of print	Pfaller	Activity of Omadacycline and Comparator Agents When Tested against Staphylococcus aureus from a Surveillance Program Conducted in North America and Europe
Aug, 2016	J. Clin. Pharmacol.	Accepted, epub ahead of print	Tzanis	Effect of Food on the Bioavailability of Omadacycline in Healthy Subjects
Aug, 2016	Xenobiotica	Accepted, epub ahead of print	Flarakos	Clinical disposition, metabolism and in vitro drug–drug interaction properties of omadacycline
Jan, 2017	Antimicrob. Agents and Chemother.	61: e01784-16	Lin	Pharmacokinetics, Distribution, Metabolism, and Excretion of Omadacycline Following a Single Intravenous or Oral Dose of ¹⁴C-omadacycline in Rats
Dec, 2016	Bioorg. Med. Chem.	24: 6409-6419	Tanaka	Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic
Dec, 2016	Antimicrob. Agents and Chemother.	60: 7431-7435	Sun	A Randomized, Open-label Study of the Pharmacokinetics and Safety of Oral and Intravenous Administration of Omadacycline to Healthy Subjects
Dec, 2016	Antimicrob. Agents and Chemother.	60: 7502-7504	Waites	In Vitro Activities of Omadacycline (PTK 0796) and Other Antimicrobial Agents Against Human Mycoplasmas and Ureaplasmas
Oct, 2016	Future Microbiol.	11: 1421-1434	Villano	Omadacycline: development of a novel aminomethylcycline antibiotic for treating drug-resistant bacterial infections
Sept, 2016	Antibiotics	5: 32	Heidrich	The Novel Aminomethylcycline Omadacycline Has High Specificity for the Primary Tetracycline-Binding Site on the Bacterial Ribosome
Sept, 2016	Antimicrob. Agents and Chemother.	60: 5247-5253	Tanaka	In Vitro and In Vivo Assessment of Cardiovascular Effects with Omadacycline

Nov, 2015	Antimicrob. Agents and Chemother.	59: 7044-7053	Honeyman	Structure-Activity Relationship of the Aminomethylcyclines and the Discovery of Omadacycline
March, 2014	Antimicrob. Agents and Chemother.	58(3): 1279–1283	Draper	Mechanism of Action of the Novel Aminomethylcycline Antibiotic Omadacycline
Feb, 2014	Antimicrob. Agents and Chemother.	58(2): 1127-1135	Macone	In Vitro and In Vivo Antibacterial Activities of Omadacycline, a Novel Aminomethylcycline
Nov, 2012	Antimicrob. Agents and Chemother.	56(11): 5650-5654	Noel	A Randomized, Evaluator-Blind, Phase 2 Study Comparing the Safety and Efficacy of Omadacycline to Those of Linezolid for Treatment of Complicated Skin and Skin Structure Infections

Posters				
Date	Conference	Presentation number	First Author	Title
Oct 26-30, 2016	IDWEEK	1827	Flamm	Activity of Omadacycline When Tested Against Gram-positive Bacteria Isolated from Patients in the USA During 2015 as Part of a Global Surveillance Program
June 16-20, 2016	ASM Microbe	MONDAY-001	Sweeney	Activity of Omadacycline Against Clinical Isolates of Neisseria gonorrhoeae, Including Ciprofloxacin-Resistant Isolates
June 16-20, 2016	ASM Microbe	MONDAY-509	Van Wart	Population Pharmacokinetics (PPK) of Omadacycline (OMC) Following Intravenous (IV) or Oral Administration and Evaluation of Phase 3 Sparse PK Sampling Strategies
June 16-20, 2016	ASM Microbe	MONDAY-510	Van Scoy	Evaluation of the In Vitro Activity Profile of Omadacycline Against Haemophilus influenzae
June 16-20, 2016	ASM Microbe	MONDAY-512	Hinshaw	Post-antibiotic Effect of Omadacycline Against Target Pathogens
June 16-20, 2016	ASM Microbe	MONDAY-518	Villano	In Vitro Protein Binding with Omadacycline, a First in Class Aminomethylcycline Antibiotic
June 16-20, 2016	ASM Microbe	MONDAY-519	Tzani	Effect of Food on the Bioavailability of Omadacycline in Healthy Volunteers
June 16-20, 2016	ASM Microbe	MONDAY-551	Dubois	In Vitro Intracellular Activity of Omadacycline against Legionella pneumophila

June 16-20, 2016	ASM Microbe	MONDAY-552	Diehl	In Vitro Activity of Omadacycline Against Escherichia coli Biofilms
June 16-20, 2016	ASM Microbe	MONDAY-567	Tracjewski	Omadacycline (PTK0796) Spectrum of Activity from 2003 through 2015
April 9-12, 2016	ECCMID	P1324	Chilton	Effects of omadacycline on gut microbiota populations and Clostridium difficile germination, proliferation and toxin production in an in vitro model of the human gut
April 9-12, 2016	ECCMID	P1323	Dubois	In Vitro Bacterial and Intracellular Activity of Omadacycline against Legionella pneumophila
April 9-12, 2016	ECCMID	P1317	Flamm	Omadacycline activity tested against European bacterial isolates from a combined 2010-2011 Global Surveillance program
April 9-12, 2016	ECCMID	P1322	Hawser	Bactericidal activity of omadacycline, a novel aminomethylcycline
April 9-12, 2016	ECCMID	P1325	Kim	Activity and Efficacy of Omadacycline against Clostridium difficile
April 9-12, 2016	ECCMID	P1318	Tanaka	Effect of Age and Gender on the Pharmacokinetics of the Oral and IV Omadacycline, A New Class of Aminomethylcyclines
April 9-12, 2016	ECCMID	P1326	Tanaka	A Pooled Analysis of Two Randomized Multicenter, Evaluator-Blind Studies Comparing the Safety and Efficacy of Omadacycline and Linezolid for the Treatment of Complicated Skin and Skin Structure Infections
April 9-12, 2016	ECCMID	P1319	Tanaka	Single and Multiple Dose Pharmacokinetics and Tolerability of Intravenous Omadacycline in Healthy Volunteers
April 9-12, 2016	ECCMID	P1320	Van Wart	Population Pharmacokinetics (PPK) of Omadacycline Following Intravenous or Oral Administration to Phase 1 Subjects
April 9-12, 2016	ECCMID	P1321	Villano	Omadacycline, an Aminomethylcycline Antibiotic, Has No Effect on QT/QTc Intervals in Healthy Subjects
Sept 17-21, 2015	ICAAC	C-554	Flamm	Activity of Omadacycline Tested against Streptococcus pneumoniae from a Global Surveillance Program (2014)
Sept 17-21, 2015	ICAAC	C-614	Flamm	Activity of Omadacycline Tested against Enterobacteriaceae Causing Urinary Tract Infections from a Global Surveillance Program (2014)
Sept 17-21, 2015	ICAAC	F-289	Flamm	Activity of Omadacycline Tested against Staphylococcus aureus from a Global Surveillance Program (2014)

Sept 17-21, 2015	ICAAC	D-194	Traczewski	Quality Control Parameters for Broth Microdilution and Agar dilution Susceptibility Tests of Omadacycline (formerly PTK-0796) against B. fragilis ATCC 25285, B. thetaiotaomicron ATCC 29741, E. lenta ATCC 43055, and C. difficile ATCC 700057 Using Fresh Media
Sept 17-21, 2015	ICAAC	D-195	Traczewski	Omacycline (formerly PTK-0796) In Vitro Spectrum of Activity and Confirmation of Disk Mass Using Fresh Media for MIC Testing
Sept 17-21, 2015	ICAAC	D-1140	Traczewski	Quality Control Parameters for Omadacycline Minimum Inhibitory Concentration (MIC) Susceptibility Tests.
Sept 17-21, 2015	ICAAC	F-770	DuBois	In Vitro Activity of Omadacycline Against Legionella pneumophila
Feb 25-27, 2013	ASM Biodefense	253(G)	Draper	In Vitro Activity of Omadacycline (OMC) against Biothreat Bacteria
Sept 9-12, 2012	ICAAC	A-1282	Ting	Pharmacokinetics of Omadacycline (PTK0796) in Subjects with Hepatic Impairment
Sept 9-12, 2012	ICAAC	A-1281	Sun	Pharmacokinetics of [14C]-labeled Omadacycline (PTK 0796) in Healthy Male Subjects
Mar 31- Apr 3, 2012	ECCMID	P694	Noel	Safety and efficacy of PTK 0796 (Omadacycline) as treatment of complicated skin and soft tissue infection (cSSTI)
Mar 31- Apr 3, 2012	ECCMID	P1422	Hanna	Metabolic Stability of PTK 0796 (Omadacycline)
Mar 31- Apr 3, 2012	ECCMID	P1423	Sun	A single-dose study to evaluate the pharmacokinetics, safety, and tolerability of multiple formulations of PTK 0796 in healthy subjects
Mar 31- Apr 3, 2012	ECCMID	P1424	Hanna	Lack of Interaction of PTK 0796 (Omadacycline) with Human Transporter
Mar 31- Apr 3, 2012	ECCMID	P1449	Flamm	Antimicrobial Activity of PTK 0796 (Omadacycline) and Comparator Agents Against Contemporary Pathogens Commonly Associated with Community-Acquired Respiratory Tract Infections Collected During 2011 from the European Union
Mar 31- Apr 3, 2012	ECCMID	P1450	Sader	Antimicrobial Activity of PTK 0796 (Omadacycline) Tested against Gram-positive Organisms Isolated from European Hospitals in 2011
Sept 17-20, 2011	ICAAC	C1-609	Ruzin	Omacycline (PTK796) Mechanism of Action Studies by Using In Vitro Protein Synthesis Inhibition Assay and Molecular Modeling

May 7-10, 2011	ECCMID	P1528	Hait	In a Phase 2 Complicated Skin and Soft Tissue Infections Trial, Outcomes Assessed Early in the Course of Therapy were Consistent with Outcomes 10-17 Days After Completing Therapy with Either Omadacycline (OMC; PTK796) or Linezolid
May 7-10, 2011	ECCMID	P1074	Leahy	Comparative Efficacy of Omadacycline (PTK796) in Lethal Streptococcus pneumoniae and Staphylococcus aureus Pneumonia Models
May 7-10, 2011	ECCMID	P1141	Macone	In vitro Activity of Omadacycline (PTK796) in Broth Plus Lung Surfactant or Human Serum
Sept 12-15, 2010	ICAAC	B-069	Yu	Efficacy of PTK796 in a Rat MRSA Infected Endocarditis (IE) Model
Sept 12-15, 2010	ICAAC	C1-1413	Ruzin	Studies on the Mechanism of Resistance to PTK796 in Pseudomonas aeruginosa and Klebsiella pneumonia
Sept 12-15, 2010	ICAAC	E-1569	Biedenbach	In Vitro Evaluation of PTK 0796 Activity Tested against Staphylococcus aureus, Including Hospital- and Community-Associated MRSA Strains from the USA and Europe
Sept 12-15, 2010	ICAAC	E-1588	Sader	Antimicrobial Activity of PTK 0796 Tested against Gram-Positive Organisms Causing Bloodstream Infections in 2009
Sept 12-15, 2010	ICAAC	K-124	Ting	Pharmacokinetics of Intravenous and Oral PTK796, A New Aminomethylcycline Antibiotic
Sept 12-15, 2010	ICAAC	L1-1760	Macone	Identification and Susceptibility of Pathogens Isolated from Patients with Complicated Skin and Skin Structure Infections (cSSSI): Results of a PTK0796 (PTK) Phase 2 Clinical Trial
Oct 25-28, 2008	ICAAC	L-1515b	Arbeit	Safety and Efficacy of PTK 0796: Results of the Phase 2 Study in Complicated Skin and Skin Structure Infections Following IV and Oral Step Down Therapy
Sept 27-30, 2006	ICAAC	F1-1971	Smith	Antistaphylococcal Activity of MK-2764 / PTK 0796 Compared to Other Agents
Sept 27-30, 2006	ICAAC	F1-1974	Craig	In Vivo Pharmacodynamics of MK-2764 / PTK 0796 Against Various Gram-positive and Gram-negative Bacteria in the Thighs of Neutropenic and Normal Mice
Sept 27-30, 2006	ICAAC	F1-1972	DuBois	In Vitro Activity of MK-2764 / PTK 0796 Against Legionella spp.
Sept 27-30, 2006	ICAAC	F1-1973	Tessier	Pharmacokinetic/Pharmacodynamic Profile of MK-2764 / PTK 0796 against S. pneumoniae in a Murine Pneumonia Model

May 1-4, 2004	ECCMID	P926	Macone	Potent activity of BAY 73-7388, a Novel Aminomethylcycline, Against Susceptible and Resistant Gram-positive and Gram-negative Organisms
May 1-4, 2004	ECCMID	P928	Endermann	BAY 73-7388 is Highly Efficacious in Animal Models of Intraabdominal Infections Caused by a Range of Aerobic and Anaerobic Organisms, Including VRE
May 1-4, 2004	ECCMID	P930	Broetz-Oesterhelt	Superior Efficacy of BAY 73-7388, a Novel Aminomethylcycline, Compared with Linezolid and Vancomycin in Murine Sepsis Caused by Susceptible or Multiresistant Staphylococci
May 1-4, 2004	ECCMID	P925	Bhatia	Activity of BAY 73-7388, a Novel Aminomethylcycline, and Other Novel Antibiotic Classes Against Resistant Bacteria In Vitro
May 1-4, 2004	ECCMID	P927	McKenney	BAY 73-7388, a Novel Aminomethylcycline, Exhibits Potent Efficacy in Pulmonary Murine Models of Infection
May 1-4, 2004	ECCMID	P929	Ladel	BAY 73-7388 Demonstrates Greater Activity than Linezolid in a Range of Murine Models of Skin and Soft Tissue Infection
May 1-4, 2004	ECCMID	P931	Endermann	BAY 73-7388, a Novel Aminomethylcycline, is Highly Active In Vivo in a Murine Model of Pneumococcal Pneumonia
Sept 14-17, 2003	ICAAC	F-751	Weir	The Mechanism of Action of PTK 0796 (BAY 73-6944)
Sept 14-17, 2003	ICAAC	F-752	Weir	The Activity of PTK 0796 (BAY 73-6944) Against Tetracycline Resistance
Sept 14-17, 2003	ICAAC	F-753	Traczewski	PTK 0796 (BAY 73-6944): In Vitro Potency and Spectrum of Activity Compared to Ten Other Antimicrobial Compounds
Sept 14-17, 2003	ICAAC	F-754	Macone	In Vitro Activity of PTK 0796 (BAY 73-6944) Against Gram-Positive and Gram-Negative Organisms
Sept 14-17, 2003	ICAAC	F-755	Bhatia	PTK 0796 (BAY 73-6944) and other Novel Tetracycline Derivatives Exhibiting Potent in vitro and in vivo Activities Against Antibiotic Resistant Gram-Positive Bacteria
Sept 14-17, 2003	ICAAC	F-756	Traczewski	PTK 0796 (BAY 73-6944): Effects of Environmental Variation on MICs and Confirmation of Disk Mass
Sept 14-17, 2003	ICAAC	F-757	McKenney	Evaluation of PTK 0796 (BAY 73-6944) in Experimental Models of Infections Caused by Gram-Positive and Gram-Negative Pathogens
Sept 14-17, 2003	ICAAC	F-758	McKenney	The Efficacy of PTK 0796 (BAY 73-6944) in Murine Models of Streptococcus pneumoniae Infections

Sept 14-17, 2003	ICAAC	F-759	Cannon	Pharmacokinetics of PTK 0796 (BAY 73-6944) in Mouse, Rat and Cynomolgus Monkey
Sept 14-17, 2003	ICAAC	F-760	Chaturvedi	In Vitro Assessment of Plasma Protein Binding and Metabolic Stability of PTK 0796 (BAY 73-6944)